drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
An autologous, gene-modified T-cell therapy engineered to express chimeric antigen receptors against CD19 and BCMA, designed to deplete CD19+ B cells and BCMA+ plasmablasts/plasma cells to reduce pathogenic autoantibodies in refractory generalized myasthenia gravis.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with chimeric antigen receptors targeting CD19 and BCMA bind these antigens on B cells and plasmablasts/plasma cells, triggering T-cell activation and cytotoxic killing (perforin/granzyme). This depletes autoantibody-producing compartments and reduces pathogenic autoantibodies in refractory generalized myasthenia gravis.
drug_name
CD19-BCMA Targeted CAR-T
nct_id_drug_ref
NCT06371040